Evidence map›Paper›PMID 34764715›Full record

ArticlePatient related outcome measures2021

Clinical Assessment of Dialysis Recovery Time and Symptom Burden: Impact of Switching Hemodialysis Therapy Mode.

Stephanie Bolton, Rachel Gair, Lars-Göran Nilsson, Michael Matthews, Louanne Stewart, Natasha McCullagh

Open access · goldAbstract read
In one paragraph

Article in Patient related outcome measures, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Fatigue in Patients Receiving Maintenance Hemodialysis: A Review.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023
    Review
  9. Expanded hemodialysis: what's up, Doc?Clinical kidney journal · 2023
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Stephanie BoltonRenal Unit, Antrim Area Hospital, Northern Health and Social Care Trust, Northern Ireland, UK.
Rachel GairUK Renal Registry, Bristol, UK.
Lars-Göran NilssonBaxter International Inc., Lund, Sweden.ORCID 0000-0003-4323-2875
Michael MatthewsRenal Unit, Antrim Area Hospital, Northern Health and Social Care Trust, Northern Ireland, UK.
Louanne StewartRenal Unit, Antrim Area Hospital, Northern Health and Social Care Trust, Northern Ireland, UK.
Natasha McCullaghRenal Unit, Antrim Area Hospital, Northern Health and Social Care Trust, Northern Ireland, UK.
Northern Health and Social Care Trust · GBBaxter (Sweden) · SERenal Association · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMost people on hemodialysis (HD) report a high symptom burden. Fatigue and lack of energy are prominent, interfering with daily life and associated with poor outcome. Prolonged recovery time after each of the thrice weekly dialysis treatments is common. The impact of HD therapies, like expanded hemodialysis (HDx), on patient reported recovery time and symptom burden is unclear.

methodsA dialysis unit decided to perform regular assessments of patient-reported symptom burden, using the POS-S Renal Symptom questionnaire and the "Recovery time from last dialysis session" question as part of routine patient focused care. At a similar time, a clinical evidence-based decision was taken to switch the in-center dialysis cohort from regular high-flux dialysis membrane to medium cut-off (MCO) membrane, introducing HDx therapy.

resultsQuarterly assessment of patient-reported symptom burden was well accepted. A sustained clinically relevant reduction in post-dialysis recovery time was observed following the therapy switch. In patients providing data up to 12 months (N = 58), median recovery time decreased from 210 min (IQR 7.5-600) to 60 min (0-210; p = 0.002) and 105 min (0-180; p = 0.001) at 6 and 12 months, respectively. Thirty-six percent of individuals reported a recovery time longer than 360 minutes at the initial assessment, which decreased to 9% at 12 months. The POS-S Renal total symptom score showed a decrease at 6 months but no difference from baseline at 12 months. The "fatigue/lack of energy" symptom showed a sustained improvement; the percentage of participants scoring its impact as "severe" or "overwhelming" decreased from 28% at baseline to 16% at 12 months. Changes in other symptoms were more variable.

conclusionRegular assessment of patient reported symptoms is feasible in routine dialysis practice and can help in evaluating the impact of clinical interventions. Observations suggest that HDx therapy may reduce post-dialysis recovery time and improve perceived fatigue level.

Indexed as

fatigueHDx therapypost-dialysis recovery timesymptom burden

Identifiers

PMID34764715
PMCPMC8575372
OpenAlexW3209881978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.